Revvity, Inc. (RVTY) Revenue by Segment
Revvity revenue by segment at a glance
In Q2 fiscal 2026 (the quarter ended July 5, 2026), Revvity's largest business segment was Diagnostics, with $370.99 million or 51% of revenue, up 4.7% from a year earlier. Next: Life Sciences (49%).
By product or service, Life Sciences Solutions brought in 41%, Immunodiagnostics brought in 29% and Reproductive health brought in 21% of revenue in Q2 fiscal 2026.
By region, Americas brought in 45%, Europe brought in 31% and Asia brought in 24% of revenue in Q2 fiscal 2026.
The fastest-growing business segment from a year earlier was Diagnostics (+4.7%).
From company filings, in USD; latest quarter ended July 5, 2026; quarterly data from Q3 fiscal 2017.
Revvity, Inc.
Revenue breakdown
Fiscal quarters, from company filings
Revvity revenue by business segment, last 4 quarters
| Business segment | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| Diagnostics | $371.0M | $349.3M | $356.1M | $354.4M | 51% |
| Life Sciences | $358.7M | $361.8M | $342.8M | $365.9M | 49% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Revvity revenue by product or service, last 4 quarters
| Product or service | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| Life Sciences Solutions | $301.0M | $300.0M | $290.5M | $298.1M | 41% |
| Immunodiagnostics | $214.8M | $201.8M | $212.7M | $218.8M | 29% |
| Reproductive health | $156.2M | $147.4M | $143.4M | $135.6M | 21% |
| Software | $57.7M | $61.8M | $52.3M | $67.8M | 8% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Revvity revenue by region, last 4 quarters
| Region | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| Americas | $325.6M | $316.0M | $307.3M | $323.6M | 45% |
| Europe | $229.0M | $223.0M | $202.4M | $203.6M | 31% |
| Asia | $175.1M | $172.1M | $189.3M | $193.1M | 24% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Questions and answers
What are Revvity's business segments?
Diagnostics and Life Sciences (as reported for Q2 fiscal 2026).
Which business segment makes the most money for Revvity?
Diagnostics: $370.99 million, or 51% of revenue, in Q2 fiscal 2026.
What are Revvity's main products and services?
By revenue in Q2 fiscal 2026: Life Sciences Solutions (41%), Immunodiagnostics (29%), Reproductive health (21%) and Software (8%).
Where does Revvity make its money?
By region in Q2 fiscal 2026: Americas (45%), Europe (31%) and Asia (24%).
